Loading...
•
Mar 31, 2021
SpringWorks Therapeutics Q1 2021 Earnings Report
Reported first quarter financial results and provided an update on recent company developments.
Key Takeaways
SpringWorks Therapeutics reported a net loss of $29.8 million, or $0.62 per share, for the first quarter of 2021. As of March 31, 2021, the company's cash, cash equivalents and marketable securities were $541.0 million.
Reported interim data from Phase 2b ReNeu Trial of Mirdametinib in NF1-PN demonstrating encouraging clinical activity and tolerability in the first 20 adult patients enrolled.
Announced achievement of first patient dosed in Allogene and Janssen Phase 1 Trials Evaluating Nirogacestat in Combination with BCMA Therapies.
Expanded Targeted Oncology Pipeline with Exclusive Worldwide License to TEAD Inhibitor Portfolio.
Continued to execute on 10 clinical programs and grew portfolio of opportunities aimed at serving a broad group of patients across three distinct oncology segments.
Forward Guidance
SpringWorks expects to report topline data from the Phase 3 DeFi trial in the second half of 2021, initial clinical data from BCMA combination trial of nirogacestat with GSK’s BLENREP in multiple myeloma and initial clinical data from metastatic solid tumor trials being conducted in collaboration with BeiGene.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...